Figure 4.

Glycosylated-PEGylation of anti-PD-L1 antibodies for creating a targeted immunotherapy against glioblastoma. The glycosylated-PEGylation allowed the active transport of the antibody through the BBTB of glioblastoma by targeting the GLUT1 on the endothelial cells. Inside the tumor, the antibodies were dePEGylated by the cleavage of the reduction-sensitive bonds. In off-target tissues, the coated antibodies remained silent, avoiding the immune-related adverse events. Reprinted with permission from reference [76]. Copyright Nature 2021.